Antiretroviral treatment has been one of the most developed pharmaceutical revolutions of all times.
With more than 20 million people on ART, a number that continue to increase, adherence to medication and safer formulations remain critical challenges to sustain the epidemic control.
Countries in resource limited settings depend heavily on external funding to purchase daily ART pills and costly laboratory tests.
Prevention with ARVs has also shown great promise, yetto be brought to scale.
Drivers of poor adherence and low retention levels vary from complexity of dosing, toxicity, stigma, affordability and supply chain issues.
Long-acting (LA) formulations of medicines to support long-term adherence and/or simplify treatment and prevention delivery could lead to increased efficiencies and greater impact on the HIV pandemic.
LA may play roles in other coinfections and comorbidities such as hepatitis, tuberculosis, or cancer.
In High-income countries, the shift from daily oral medication to weekly, monthly,and less frequent long-acting formulations has reported better health outcomes in diverse areas such as schizophrenia, chronic asthma, and it is now also an option in opioid substitution therapy.
In sub-Saharan Africa, LA hormonal contraception, as an injection or implant, has become the method of choice for most women of reproductive age where accessible.
For HIV, active research is ongoing to develop LA formulations for treatment and prevention.
Several LAproducts are yet in early stages of development, with a few only already in clinical phases and/or submitted for regulatory review.
For commonco-infections, new technologies offer as well potential such as in hepatitis C Virus treatment or treatment of latent tuberculosis infection.
Despite their promise, LA technologies are likely to pose substantial challenges for early adoption in low and middle-income countries and developing a healthy market for LA products might be more challenging than for conventional, oral medications.
This satellite session will provide an overview of LA product development and discuss the opportunities and challenges for introduction of LA therapy and prevention in HIV programmes in sub-Saharan Africa.
Approximately 200 participants will attend the satellite, representing community expertise, national programme managers, industry and researchers focused on innovation in delivery methods for pharmaceuticals, international implementing agencies,intergovernmental organizations and funders.